Shop

The most-studied dual stack in growth hormone research. CJC-1295 amplifies natural GH release pulses while Ipamorelin selectively triggers GH without affecting cortisol or prolactin — published studies show synergistic IGF-1 elevation well beyond either peptide alone.

A copper-binding tripeptide naturally found in plasma — one of the most-cited compounds in skin and longevity research. A landmark study showed GHK-Cu modulated 4,192 human genes toward younger expression patterns, with collagen synthesis pathways significantly upregulated.

A research blend combining three of the most-cited compounds in tissue science. GHK alone has been shown to modulate 4,192 human genes toward younger expression patterns, while BPC-157 and TB-500 support underlying repair pathways across hundreds of published studies.

A dual-receptor agonist targeting both GIP and GLP-1 receptors simultaneously — one of the most-studied compounds in modern metabolic research. The dual-incretin mechanism distinguishes it from single-pathway research compounds developed in earlier generations.

A triple-receptor research compound activating GIP, GLP-1, and glucagon receptors simultaneously — currently the most-watched molecule in metabolic science. The glucagon receptor component expands the mechanism beyond incretin pathways into energy expenditure research.

A mitochondrial-derived peptide that signals from mitochondria to the rest of the cell — discovered in 2015 and now one of the most active areas in longevity research. Studies in animal models have shown improved insulin sensitivity and a 26% increase in running endurance.

The coenzyme behind every mitochondrial energy reaction in the body — and central to virtually all longevity research published in the last decade. NAD+ levels decline approximately 50% by age 50, which is why restoration of this cofactor sits at the core of aging science.

The only GHRH analog, originally developed for HIV-associated visceral adiposity research. Clinical trials demonstrated 15-18% reductions in visceral adipose tissue at 26 weeks — without affecting subcutaneous fat or insulin sensitivity.

A small-molecule inhibitor of NNMT, an enzyme upregulated in obese adipose tissue. Research in diet-induced obesity models demonstrated significant reductions in fat mass without changes to food intake — a mechanism distinct from every other compound in metabolic research.

Sterile water with 0.9% benzyl alcohol added as a preservative — the standard solvent used in peptide reconstitution research. Each vial supports multiple withdrawals over 28 days, making it essential infrastructure for any peptide research workflow.

The most-studied "body protection compound" in tissue research — a 15-amino-acid sequence derived from human gastric juice. Animal studies have demonstrated 50-72% acceleration in tendon and ligament healing, with parallel effects on angiogenesis and gut lining repair.

The two most-researched recovery peptides paired in a single vial. Studies on each show complementary mechanisms — BPC-157 accelerates soft tissue and gut repair, TB-500 mobilizes stem cells to injury sites — making this the most-requested combination in recovery research.

The extended-release variant, with a Drug Affinity Complex pushing half-life from minutes to approximately 8 days. Studies show sustained GH and IGF-1 elevation across multi-day windows, making it useful in research requiring stable hormone levels rather than pulses.

A GHRH analog that amplifies natural growth hormone pulses without extending half-life — preserving the body's pulsatile release pattern. Research demonstrates significant elevations in both GH and downstream IGF-1 levels following administration in study models.

A tetrapeptide developed by Russian researcher Vladimir Khavinson and studied for its effects on telomerase activity. A 12-year study in elderly populations reported a 50% reduction in mortality rates over the observation window — among the most striking results in bioregulator research.

Human Chorionic Gonadotropin — a glycoprotein hormone with decades of clinical research and FDA-approved applications. In male research models, HCG has been shown to stimulate testicular Leydig cells to produce testosterone via LH-mimicking pathways, with extensively documented effects.

The most selective growth hormone releaser ever developed for research — triggering GH release without affecting cortisol, prolactin, or appetite. Studies show clean, pulse-like GH release that mimics natural patterns more closely than older secretagogues like GHRP-6.

The Glow Blend formulation with KPV added — an anti-inflammatory tripeptide studied for skin and gut barrier integrity. Research across these four compounds spans wound healing, collagen synthesis, and inflammatory pathway modulation in thousands of published studies.

A tripeptide fragment of alpha-MSH studied extensively for anti-inflammatory effects in gut and skin tissue. Research has demonstrated downregulation of inflammatory cytokines including TNF-α and IL-6, positioning it as a novel research compound in barrier-function science.

The body's master antioxidant — a tripeptide central to nearly every detoxification pathway studied. Research spans thousands of published studies on oxidative stress, liver function, and cellular protection, making it one of the most-cited compounds in redox biology.

A synthetic analog of alpha-MSH studied extensively for its effects on melanocortin receptors. Research has investigated its role in melanin production pathways and central nervous system effects on libido — making it one of the most multi-functional compounds in MC receptor science.

A short peptide bioregulator developed in the Khavinson research program, targeting pineal gland function and circadian biology. Research has investigated its effects on cognitive markers, neural protection, and cellular aging pathways in elderly and stressed animal models.

A melanocortin receptor agonist that acts on the central nervous system rather than the vascular system — mechanistically distinct from every PDE5 inhibitor. The FDA-approved version (Vyleesi) holds clinical data demonstrating efficacy in female sexual dysfunction research.

A synthetic analog of tuftsin developed alongside Semax in Russian research programs. Studies have investigated its effects on GABA system modulation and anxiety markers, with comparable efficacy to benzodiazepine compounds in animal models — but without sedation in the published data.

A synthetic ACTH analog developed in Russia and approved there for stroke recovery research. Studies have demonstrated significant increases in BDNF — brain-derived neurotrophic factor — one of the most-studied markers in neuroplasticity, cognition, and neural repair research.

A synthetic fragment of Thymosin Beta-4, the protein the body upregulates at every injury site. Over 100 published studies have investigated its effects on muscle, tendon, and cardiac tissue repair, with research demonstrating accelerated stem cell mobilization to damaged areas.

A research blend pairing the FDA-approved GHRH analog Tesamorelin with the selective GH-releaser Ipamorelin. The combination targets both arms of the GH axis simultaneously — a synergy well-documented in growth hormone literature for amplifying IGF-1 response.

A 28-amino-acid peptide isolated from the thymus gland — approved as a pharmaceutical (Zadaxin) in over 30 countries for immune research applications. Over 70 clinical trials have studied its effects on immune cell signaling, T-cell function, and viral response markers.